Abstract 4619
Background
Inflammation impacts each step of tumorigenesis, including tumor initiation, promotion and metastatic progression. Biomarkers including the neutrophil, lymphocyte and platelet count, as well as the neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and monocyte-lymphocyte ratio (MLR) are indices of inflammation. The aim of the present study was to assess the blood the neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and monocyte-lymphocyte ratio (MLR) as a prognostic factors in male breast cancer patients (BC).
Methods
A the retrospective analysis of 38 male BC patients who were treated at COI (Gliwice, Poland) between January 2005 and December 2018 was performed. Based on the cut-off values determined, the NLR was considered as ‘elevated’ at > 2.65, the MLR value was ‘elevated’ at > 0.28 and the PLR was considered ‘elevated’ at > 190.9. The prognostic value (OS) of the pre-treatment PLR, NLR and MLR was assessed by univariate analysis.
Results
There was observed tendency to worse 5-year OS in male BC patients with lymph node metastases (N+) (43.5% vs. 73.9%, p = 0.171); higher tumor size (T4 vs. T1) (42% vs.85.79%, p = 0.128); negative steroid receptor status (PR-) (28.6% vs. 65.6%, p = 0.109). Patients with cancer family history had significantly better 5-year OS than patients without cancer family history (86.3% vs.35.0%, p = 0.004).Younger male BC patients (age ≤53 years) had better 5 year OS in comparison to patients over 53 years (88.9% vs. 43.1%, p = 0.014).The 5-year OS was lower in patients with lower lymphocyte value ≤1.52 (24.0% vs. 67.4%, p = 0.010). There was reported tendency to the worse 5-year OS in patients with higher PLT value (PLT>193 x 10^3) (47.3% vs. 78.8%, p = 0.157). The 5-year OS was lower in the NLR >2.75 compared with that in the NLR≤2.75 group (29.6% vs. 64.4%, p = 0.031). Similarly, a worse OS rate was associated with an elevated PLR (>114.5) (34.4% vs.77.5%, p = 0.021). There was detected tendency to worse OS in group with lower MLR level (≤3.23) (39.5% vs. 71.9%, p = 0.155).
Conclusions
The present results revealed that an elevated NLR (>2.75) and PLR (>114.5) are associated with poor OS in male breast cancer patients. In contrary, the elevated MLR affected better OS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
MSC Memorial Cancer Center and Institute of Oncology, Gliwice Branch.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5105 - Fresh blood Immune cell monitoring in patients treated with nivolumab in the GETUG-AFU26 NIVOREN study: association with toxicity and treatment outcome
Presenter: Aude DESNOYER
Session: Poster Display session 3
Resources:
Abstract
1877 - Advanced clear-cell renal cell carcinoma (accRCC): association of microRNAs (miRNAs) with molecular subtypes, mRNA targets and outcome.
Presenter: Annelies Verbiest
Session: Poster Display session 3
Resources:
Abstract
5543 - Prior tyrosine kinase inhibitors (TKI) and antibiotics (ATB) use are associated with distinct gut microbiota ‘guilds’ in renal cell carcinoma (RCC) patients
Presenter: Valerio Iebba
Session: Poster Display session 3
Resources:
Abstract
2689 - mTOR mutations are not associated with shorter PFS and OS in patients treated with mTOR inhibitors
Presenter: Cristina Suarez Rodriguez
Session: Poster Display session 3
Resources:
Abstract
3069 - Efficacy of immune checkpoint inhibitors (ICI) and genomic alterations by body mass index (BMI) in Advanced Renal Cell Carcinoma (RCC)
Presenter: Aly-Khan Lalani
Session: Poster Display session 3
Resources:
Abstract
5089 - Finding the Right Biomarker for Renal Cell Carcinoma (RCC): Nivolumab treatment induces the expression of specific peripheral lymphocyte microRNAs in patients with durable and complete response.
Presenter: Lorena Incorvaia
Session: Poster Display session 3
Resources:
Abstract
2594 - Algorithms derived from quantitative pathology can be a gatekeeper in patient selection for clinical trials in localised clear cell renal cell carcinoma (ccRCC)
Presenter: In Hwa Um
Session: Poster Display session 3
Resources:
Abstract
2566 - High baseline blood volume is an independent favorable prognostic factor for overall and progression-free survival in patients with metastatic renal cell carcinoma
Presenter: Aska Drljevic-nielsen
Session: Poster Display session 3
Resources:
Abstract
2675 - Impact of estimand selection on adjuvant treatment outcomes in renal cell carcinoma (RCC)
Presenter: Daniel George
Session: Poster Display session 3
Resources:
Abstract
1541 - TERT gene fusions characterize a subset of metastatic Leydig cell tumors
Presenter: Bozo Kruslin
Session: Poster Display session 3
Resources:
Abstract